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INTRODUCTION:  Lactobacillus  species  are  probiotics  proven  to exhibit  various  preventative  as  well  as
therapeutic  properties.  While  lactobacillus  species  have  been  implicated  in the  formation  of dental  caries,
endocarditis  and  bacteremia,  their  role  as  pathogens  in  cholecystitis  has not  been  reported.  We  present
a  rare  case  of Lactobacillus  fermentum  working  as  a  pathogen  in cholecystitis.
PRESENTATION OF  CASE:  An 81-year  old  male  was  admitted  with  right  upper  quadrant  abdominal  pain.
His  signs,  symptoms,  laboratory  values  and imaging  were  consistent  with  a diagnosis  of  cholecystitis
with  ascending  cholangitis.  In  view  of  his  co-morbidity  and  severe  sepsis,  the  patient  was  treated  non-
operatively  with  antibiotics  and  cholecystostomy.  L.  fermentum,  which  was vancomycin  resistant,  was
identiﬁed  from  the  cholecystostomy  aspirate  and  from  anaerobic  blood  culture.  The  patient  went  into
septic  shock,  developed  multi-organ  dysfunction  syndrome  and  eventually  died.holangitis
ulti-organ dysfunction syndrome
DISCUSSION: Commensal  bacteria  such  as L.  fermentum  are  known  to modulate  immunity,  reduce  the
pathogenicity  of  gastrointestinal  organisms  and  play  a therapeutic  role  in  various  disease  processes.  We
isolated  L. fermentum  as a pathogen  in a documented  case  of cholecystitis  with  ascending  cholangitis.
CONCLUSION: While  the  routine  use  lactobacillus  species  as  a probiotic  is  supported  in the  literature,
understanding  its  potential  role  as a pathogen  may  allow  more  judicious  use  of these  bacteria  and
encourage  research  to  elucidate  the  pathogenicity  of  lactobacillus  species.
gical © 2013 Sur
. Introduction
Within the past few decades, research has shed light on the com-
lex relationship between the normal ﬂora of the human body and
he changes that occur with the use of antibiotics.1,2 The alteration
f this complex balance between the normal ﬂora and ingested
icrobes has explained the pathophysiology of disease entities
uch as clostridial infection in the colon.3 Commensal bacteria
uch as the lactobacillus species have been shown to play an inte-
ral role in preventing colonization by potential pathogens in the
olon and are thus designated probiotics.1,4,5 Oral administration
f probiotics has been shown to enhance innate immunity, as well
s having antimicrobial and antioxidative activitiy.6,7 Probiotics
ave also been shown to be beneﬁcial in a wide range of disease
rocesses, from urinary tract infection to bacterial vaginosis.8 On
he other hand, lactobacillus species have been reported to act as
athogens in dental caries, endocarditis and bacteremia. However,
eview of the literature does not reveal any episode of this pro-
iotic acting as a pathogen in cholecystitis.9–11,13,14 We  report an
1-year male who was diagnosed with cholecystitis and ascending
∗ Corresponding author at: New York Methodist Hospital, Department of Surgery,
06  Sixth Street, Brooklyn, NY 11215, United States. Tel.: +1 508 450 9820;
ax: +1 718 780 3154.
E-mail  address: jchery03@yahoo.com (J. Chery).
210-2612 © 2013 Surgical Associates Ltd. Published by Elsevier Ltd. 
ttp://dx.doi.org/10.1016/j.ijscr.2013.04.034
Open access under CC BYAssociates Ltd. Published by Elsevier Ltd. 
cholangitis, from whom Lactobacillus fermentum was isolated as the
likely pathogen.
2.  Case report
An  81-year old male with a past medical history of diabetes
mellitus, coronary artery disease, hypertension and dyslipidemia,
presented with right upper quadrant abdominal pain. The pain
started two  weeks prior to admission, during a recent visit to
the South America. His initial symptom was  vague upper abdom-
inal discomfort, which progressed. One week prior to admission
the pain became constant, sharp, severe, non-radiating and local-
ized to the right upper quadrant. It was associated with nausea
and non-bilious vomiting. He reported feeling hot but not shiv-
ery. While eating worsened the pain, nothing made it better. He
reported increasing distension of his abdomen. He had a normal
bowel movement two  days prior to admission, a normal interval
for him. He also had dysuria and persistent hypertension that was
previously well controlled.
On  physical examination the patient’s vital signs were within
normal limits. He was an obese, elderly, black male in no acute dis-
tress. He had scleral icterus and the base of his tongue was yellow.
Open access under CC BY-NC-ND license. His obese abdomen was  distended with no visible surgical scars; it
was dull to percussion and soft to palpation with upper abdominal
tenderness, maximal in the right upper quadrant. He had a positive
Murphy’s sign. He had no other signiﬁcant physical signs.
-NC-ND license. 
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His blood tests revealed a leukocytosis with a white blood count
f 13.1 K/L, (normal 4–10.3 K/L), anemia with hemoglobin of
.2 g/dL (normal 12.5–16.9 mg/dL), a mildly elevated international
ormalized ration of 1.7 and acute renal failure with a creati-
ine of 3.70 mg/dL (normal 0.67–1.17). His liver function tests
ere abnormal with direct and total bilirubin of 4.4 mg/dL (normal
–0.2 mg/dL), and 4.9 mg/dL (normal 0.2–1.0 mg/dL), respectively.
is alkaline phosphatase was 526 u/L (normal 50–136 u/L). A right
pper quadrant ultrasound demonstrated cholelithiasis, gall blad-
er wall thickening and peri-cholecystic ﬂuid. The common bile
uct (CBD) was normal in caliber and did not contain any stones.
is urine culture was positive for candida.
The patient’s history, physical ﬁndings, biochemical values and
maging appeared consistent with cholecystitis and ascending
holangitis. However, given his multiple co-morbid conditions,
rolonged history of abdominal pain and presenting sepsis, a
ecision was made to manage the patient non-operatively. The
ntibiotics, aztreonam and metronidazole for gram negative and
naerobic coverage respectively, were started. He was  admitted
o the surgical intensive care unit. Micafungin was added for the
andiduria and the probiotic Lactobacillus acidophilus was also
tarted on the day of admission. On hospital day 1, magnetic res-
nance cholangio-pancreatography demonstrated a normal CBD,
ntra-hepatic and extra-hepatic ducts. Endoscopic ultrasound was
egative for any CBD pathology.
The  patient initially responded to the aforementioned ther-
py; his leukocytosis improved, he was afebrile and his mentation
mproved. However, his condition began to deteriorate by hospi-
al day 8. He had a progressive increase in total bilirubin, which
eaked at 20 mg/dL, and increased coagulopathy. On hospital day
 he became hypoxic with depressed mental status, requiring
ndotracheal intubation. An abdominal computed tomography
CT) scan demonstrated pericholecystic inﬂammatory changes and
uid, suggestive of gallbladder perforation with possible hepatic
bscess. A CT guided cholecystostomy was performed that same
ay. 150 ml  of dark brown ﬂuid was aspirated. Cultures from
he cholecystostomy aspirate grew L. fermentum, resistant to van-
omycin. Blood cultures sent the same day came back with the same
icrobiology, whereas the blood cultures drawn on admission did
ot have any bacterial growth. Subsequently the antibiotics were
witched to linezolid, to which the organism was sensitive. The
atient remained on linezolid throughout his hospitalization. The
actobacillus probiotic was discontinued at that time. The patient
ontinued to deteriorate.
On  hospital day 13, a repeat CT of the abdomen demonstrated
egression of the gallbladder and hepatic collection, but ascites was
een. CT guided drainage was performed of the ﬂuid: it was clear
nd straw colored and there was no growth on culture. Repeat CT of
he abdomen on hospital day 20 showed complete resolution of the
iver abscess and ascitic ﬂuid. Although the initial source of infec-
ion appeared controlled, the patient’s candiduria persisted, and he
eveloped pneumonia. Micafungin had been switched to ﬂucona-
ole on hospital day 10, and the antibiotic coverage was broadened
o include piperacillin/tazobactam (Zosyn) to cover the pneumonia,
he sensitivity determined on culture of broncheo-alveolar lavage.
inezolid was continued. Despite these measures, he developed
verwhelming sepsis, requiring norepinephrine and vasopressin
rips. On hospital day 25, he became agitated, bit on his endotra-
heal tube, had a cardiac arrest and was successfully resuscitated,
ut died on hospital day 26.. Discussion
The beneﬁcial interaction between probiotics and the endoge-
ous ﬂora in the gastrointestinal tract is clear.11,12,15 Hence forPEN  ACCESS
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the  foreseeable future, probiotic administration, particularly when
antibiotics are being used, would seem to be acceptable practice.16
However, there have been many reports in the literature implicat-
ing lactobacillus as the pathogen for various infections, particularly,
bacteremia and endocarditis, with the lactobacillus species casei
and rhamnosus being the commonest culprits.13–15 Previous
reports suggested that the incidence of infections caused by lac-
tobacilli species is very low (0.08–0.2%)14–16 and such infection on
its own  is rarely fatal.13 However co-infection with lactobacillus
species can be a marker of severe infection and risk factor for pro-
longed hospitalization, or even death.15,16 A retrospective review of
200 cases,16 quoted an overall mortality of 30% with a greater mor-
tality associated with polymicrobial infection.16 Since Lactobacilli
are part of the normal ﬂora of the gastrointestinal and genitouri-
nary tracts,13 it can be difﬁcult to determine when an infection
is caused by an endogenous species or one that is administered.
There is a theoretical risk of potential transmigration of probio-
tics in the gastrointestinal tracts leading to colonization or even
infection, through the alteration of normal physiology.17 However,
the literature has not demonstrated a link between administered
probiotics and subsequent infections.14 Our patient received L. aci-
dophilus early in his admission, a different species from the L.
fermentum that we  isolated. Therefore, it is likely that the pathogen
was endogenous within his gastrointestinal tract. Nevertheless, we
discontinued the probiotic once the culture was ﬁnalized.
We  believe that the lactobacillus species isolated in our patient
was serving as a pathogen as opposed to mere colonization, espe-
cially as this particular antibiotic-resistant strain of lactobacillus
was isolated from two normally sterile sites. Although the pathogen
was not cultured until day 9, we  believe it to be the source of the
patient’s initial symptoms rather than an opportunistic or super-
seding infection. While lactobacillus is usually isolated as part of a
polymicrobial infection, our patient did not have any other bacteria
grown on culture. This supports the argument that the bacterium
served as a primary pathogen. On presentation, the patient received
antibiotics for gram-negative coverage; whilst this practice suf-
ﬁces for most cases of cholecystitis18 it was  not adequate for the
L. fermentum in our patient. The natural history prevailed and he
deteriorated. This would explain why  his initial blood culture was
negative. The blood culture sent on hospital day 9 was positive for
L. fermentum, the same strain identiﬁed from the cholecystostomy
aspirate. When placed on appropriate antibiotics, the patient’s clin-
ical condition initially improved but concomitant infections (of the
urinary tract, and pneumonia) contributed to his demise.
The  literature suggests that early cholecystectomy (within
48–72 h of the onset of symptoms) can lead to a better out-
come in acute cholecystitis.19,20 But, there is also evidence that
elderly patients with multiple co-morbid conditions do better with
non-operative management of acute cholecystitis.21 Our patient
presented two weeks after the onset of his symptoms, with clin-
ical evidence of sepsis. Operative management was therefore not
deemed a wise choice especially as he had improved initially on
appropriate antibiotics, with adequate percutaneous drainage. His
clinical course suggests that the development of pneumonia and
unresolved candiduria, in addition to his overwhelming systemic
response, played a greater role to his demise than the cholecysti-
tis. This assessment is supported by the literature on lactobacillus
infections, which usually serve as a nidus for other infections.16
4. ConclusionTo our knowledge, this is the ﬁrst report of a lactobacillus species
being implicated in cholecystitis. Although this report would not
justify discontinuing all use of lactobacillus species as a probiotic,
it does however highlight a potential risk from the liberal use of
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acteria with pathogenic potential and may  stimulate research into
ow this species can transform to a pathogen.
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